We are thrilled to announce that Bart Bergstein has joined Genewity as our Chief Financial Officer (CFO), effective May 2024. Bart brings to the team a wealth of experience and a proven track record in the financial and life sciences sectors.

‍

As a co-founder of Forbion Capital Partners, a leading European venture capital firm, Bart has invested in numerous healthcare companies and served on the boards of many portfolio companies. His operational expertise includes his role as CFO of Cellnovo Group SA, where he successfully led the company’s IPO on Euronext Paris.

‍

Bart’s career began in 1990 at ABN AMRO Bank, where he founded the life sciences team within ABN AMRO Private Equity. His leadership in this sector continued to flourish as he spearheaded the creation of Forbion Capital Partners.

‍

In addition to his executive roles, Bart served in several non-executive board positions of sciences companies and is currently Chairman of the Board of Lead Pharma. He served as Vice Chairman of the Mibiton Foundation, which supports the Dutch biotech industry with equipment loans.

‍

Bart will lead our financing strategy and to advance our lead products into clinical development. We are proud to welcome Bart to the Genewity team and look forward to working with him to bring our products to the next phase.

‍